PE34297A1 - SPECIFIC LEAGUES OF NEUROPEPTIDE Y1 - Google Patents
SPECIFIC LEAGUES OF NEUROPEPTIDE Y1Info
- Publication number
- PE34297A1 PE34297A1 PE1996000325A PE00032596A PE34297A1 PE 34297 A1 PE34297 A1 PE 34297A1 PE 1996000325 A PE1996000325 A PE 1996000325A PE 00032596 A PE00032596 A PE 00032596A PE 34297 A1 PE34297 A1 PE 34297A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- hydrogen
- hydroxyl
- neuropeptide
- alcoxy
- Prior art date
Links
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 3
- -1 HALOGEN RADICALS Chemical class 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A COMPUESTOS DE FORMULA GENERAL (I), PREFERENTEMENTE TAL COMO LA FORMULA (II), EN DONDE: Ar ES FENILO, 2-, 3- O 4-PIRIDILO, ENTRE OTROS GRUPOS ARILO, LOS CUALES SE ENCUENTRAN OPCIONALMENTE CON 1 o 2 SUSTITUCIONES DE RADICALES HIDROXILO O HALOGENO, ENTRE OTROS; B ES OXIGENO, N(R5) O C(R5)(R6), ENTRE OTROS; n ES 1; 2 o 3; m ES 2; 3 o 4; R1 Y R2 SON HIDROGENO O ALQUILO C1-C6; R3 Y R4 SON HIDROGENO, ALQUILO C1-C6 O ALCOXI C1-C6; R5 ES ALQUILO C1-C6 O FENILO, ENTRE OTROS; A Y R6 SON HIDROGENO, HIDROXILO, AMINO, ALQUILO C1-C6 O FENILO, ENTRE OTROS; W, X, Y Y T SON HIDROGENO, HIDROXILO, HALOGENO, ALQUILO C1-C6 O ALCOXI C1-C6; R9 ES PREFERENTEMENTE HIDROGENO O METILO. ESTOS COMPUESTOS ACTUAN INHIBIENDO LOS RECEPTORES DEL NEUROPEPTIDO HUMANO Y1 (NPY1), SIENDO USADOS EN EL TRATAMIENTO DE CONDICIONES TALES COMO LA OBESIDAD, LA BULIMIA, ENTRE OTRASIT REFERS TO COMPOUNDS OF GENERAL FORMULA (I), PREFERABLY SUCH AS FORMULA (II), WHERE: Ar IS FENILO, 2-, 3- OR 4-PIRIDILO, AMONG OTHER ARILO GROUPS, WHICH ARE OPTIONALLY WITH 1 o 2 SUBSTITUTIONS FOR HYDROXYL OR HALOGEN RADICALS, AMONG OTHERS; B IS OXYGEN, N (R5) O C (R5) (R6), AMONG OTHERS; n IS 1; 2 or 3; m ES 2; 3 or 4; R1 AND R2 ARE HYDROGEN OR C1-C6 ALKYL; R3 AND R4 ARE HYDROGEN, C1-C6 ALKYL OR C1-C6 ALCOXY; R5 IS C1-C6 ALKYL OR PHENYL, AMONG OTHERS; A AND R6 ARE HYDROGEN, HYDROXYL, AMINO, C1-C6 ALKYL OR PHENYL, AMONG OTHERS; W, X, Y and T ARE HYDROGEN, HYDROXYL, HALOGEN, C1-C6-ALKYL OR C1-C6-ALCOXY; R9 IS PREFERABLY HYDROGEN OR METHYL. THESE COMPOUNDS ACT BY INHIBITING THE RECEPTORS OF THE HUMAN NEUROPEPTIDE Y1 (NPY1), BEING USED IN THE TREATMENT OF CONDITIONS SUCH AS OBESITY, BULIMIA, AMONG OTHERS
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48497495A | 1995-06-07 | 1995-06-07 | |
| US47838395A | 1995-06-07 | 1995-06-07 | |
| PCT/US1995/014472 WO1996014307A1 (en) | 1994-11-07 | 1995-11-07 | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE34297A1 true PE34297A1 (en) | 1997-09-24 |
Family
ID=27045885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000325A PE34297A1 (en) | 1995-06-07 | 1996-05-08 | SPECIFIC LEAGUES OF NEUROPEPTIDE Y1 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0833823A1 (en) |
| JP (1) | JPH10507203A (en) |
| AU (1) | AU5578796A (en) |
| BR (1) | BR9609334A (en) |
| CA (1) | CA2220958A1 (en) |
| CO (1) | CO4700426A1 (en) |
| IL (1) | IL117997A0 (en) |
| MA (1) | MA23860A1 (en) |
| PE (1) | PE34297A1 (en) |
| TR (1) | TR199600382A2 (en) |
| WO (1) | WO1996040660A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998003493A1 (en) * | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
| US6133265A (en) * | 1996-07-23 | 2000-10-17 | Neurogen Corporation | Certain amido- and amino- substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
| EP0915859B1 (en) * | 1996-07-23 | 2003-01-02 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| US6245817B1 (en) | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
| US6048900A (en) | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
| CA2251580A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
| EP0910565A1 (en) * | 1997-02-14 | 1999-04-28 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| US6420130B1 (en) | 1998-12-14 | 2002-07-16 | Aurora Biosciences Corporation | Optical molecular sensors for cytochrome P450 activity |
| DK1140888T3 (en) * | 1998-12-14 | 2003-08-25 | Vertex Pharma San Diego Llc | Optical molecular sensors for cytochrome P450 activity |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| DE602004026289D1 (en) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminyl INHIBITORS |
| ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CN1918131B (en) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | Novel inhibitors of glutaminyl cyclase |
| EP1834953A1 (en) | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors |
| JP5379692B2 (en) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| DK3461819T3 (en) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | GLUTAMINYL CYCLASE INHIBITORS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
| HUT54666A (en) * | 1989-04-22 | 1991-03-28 | Wyeth John & Brother Ltd | Process for producing peperazine derivatives and pharmaceutical compositions containing them |
-
1996
- 1996-04-22 IL IL11799796A patent/IL117997A0/en unknown
- 1996-04-26 CA CA002220958A patent/CA2220958A1/en not_active Abandoned
- 1996-04-26 BR BR9609334A patent/BR9609334A/en not_active Application Discontinuation
- 1996-04-26 AU AU55787/96A patent/AU5578796A/en not_active Abandoned
- 1996-04-26 JP JP9500490A patent/JPH10507203A/en active Pending
- 1996-04-26 EP EP96913198A patent/EP0833823A1/en not_active Withdrawn
- 1996-04-26 WO PCT/US1996/005843 patent/WO1996040660A1/en not_active Ceased
- 1996-05-08 MA MA24226A patent/MA23860A1/en unknown
- 1996-05-08 PE PE1996000325A patent/PE34297A1/en not_active Application Discontinuation
- 1996-05-08 CO CO96022963A patent/CO4700426A1/en unknown
- 1996-05-10 TR TR96/00382A patent/TR199600382A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA23860A1 (en) | 1996-12-31 |
| MX9709980A (en) | 1998-03-29 |
| JPH10507203A (en) | 1998-07-14 |
| TR199600382A2 (en) | 1996-12-21 |
| IL117997A0 (en) | 1996-10-31 |
| CO4700426A1 (en) | 1998-12-29 |
| EP0833823A1 (en) | 1998-04-08 |
| WO1996040660A1 (en) | 1996-12-19 |
| CA2220958A1 (en) | 1996-12-19 |
| BR9609334A (en) | 1999-05-25 |
| AU5578796A (en) | 1996-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE34297A1 (en) | SPECIFIC LEAGUES OF NEUROPEPTIDE Y1 | |
| AR008384A1 (en) | TOPIC COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS, USE OF THE COMPOUND FOR THE PREPARATION OF A NON-THERAPEUTIC MEDICINAL PRODUCT AND METHOD FOR SKIN POLISHING AND HAIR SOFTENING. | |
| AR006867A1 (en) | TOPIC SKIN COMPOSITION INCLUDING AN OXA-DIÁCIDO COMPOUND, ITS USE TO PREPARE A MEDICATION TO TREAT SKIN CONDITIONS AND NON-THERAPEUTIC COSMETIC METHODS FOR SKIN POLISHING AND TO SOFTEN THE APPLIED HAIR. | |
| DE69504300D1 (en) | GEM BIT-SUBSTITUTED AZACYCLIC TACHYKININ ANTAGONISTS | |
| DK0736039T3 (en) | Compounds with growth hormone-releasing properties | |
| DK0687268T3 (en) | Spiroazacyclic derivatives as substance P antagonists | |
| DE69327541D1 (en) | 4-arylmethyloxymethyl piperidine als tachykinin antagonisten | |
| MY135841A (en) | Novel benzodioxoles | |
| PE50994A1 (en) | DERIVATIVE OF 1.5 BENZODIAZEPINA | |
| PE20030703A1 (en) | 17B-HYDROXIESTEROID DEHYDROGENASE TYPE 3 INHIBITORS | |
| DE69227458D1 (en) | TRYPTAMINE ANALOG, THEIR PRODUCTION AND USE AS 5-HT1-LIKE RECEPTORS OR 5-HT2 RECEPTOR AGONISTS | |
| MY110226A (en) | Therapeutic heterocyclic compounds. | |
| GB9524157D0 (en) | Therapeutic agents | |
| PE41796A1 (en) | ACTIVE COMPOUND IN THE 5-HT SEROTONIN RECEPTOR, USEFUL IN THE TREATMENT OF DISEASES OF S.N.C. | |
| ES2113081T3 (en) | 1,4-BENZOTIAZEPINES USEFUL AS NEUROLOGICAL AGENTS. | |
| SE9702564D0 (en) | New compounds | |
| NZ528997A (en) | Sulfonamides | |
| EP0518819A3 (en) | Amidino compounds, their manufacture and use as medicament | |
| PA8575001A1 (en) | FLUOROBENZAMIDS AS MAOB INHIBITORS | |
| ID26622A (en) | 2-BENZYLAMINO-2-PHENYL-ACETAMIDE REPLACEMENT COMPOUNDS | |
| NO983178L (en) | Use of 3,4-diphenylchromanes in the preparation of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms | |
| PE20040750A1 (en) | DERIVATIVES OF N- (1-ACETYLPIPERIDIN-4-IL) -4-BENZIDRIL-2-ISOPROPILPIPERAZIN-1-CARBOXAMIDE AS INHIBITORS OF 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 | |
| PE25998A1 (en) | DERIVATIVES OF OCTAHIDRO-PIRROLO (1,2-a) -PIRAZINA 2,7-SUBSTITUTED | |
| DE69307895D1 (en) | THERAPEUTIC USE OF PHOSPHORYL-L-SERINE-N-ACYL-SPHINGOSINE | |
| GR3023757T3 (en) | Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |